109 related articles for article (PubMed ID: 2678304)
1. [A new antihypertensive: ketanserin].
Salvini P
Riv Eur Sci Med Farmacol; 1989 Feb; 11(1):77-84. PubMed ID: 2678304
[TBL] [Abstract][Full Text] [Related]
2. [Blockade of 5-HT2 receptors as a mechanism of antihypertensive action of ketanserin].
Prostran M
Srp Arh Celok Lek; 1994; 122(3-4):99-102. PubMed ID: 17972821
[TBL] [Abstract][Full Text] [Related]
3. Do hybrid drugs offer an additional benefit over pure alpha 1-blockade for hypertensive patients?
Doyle AE
J Hypertens Suppl; 1988 Dec; 6(2):S51-3. PubMed ID: 2906701
[TBL] [Abstract][Full Text] [Related]
4. Age-related effects of 5-HT2 antagonists.
Doyle AE
J Cardiovasc Pharmacol; 1991; 17 Suppl 5():S29-34. PubMed ID: 1717770
[TBL] [Abstract][Full Text] [Related]
5. Ketanserin-induced baroreflex enhancement in spontaneously hypertensive rats depends on central 5-HT(2A) receptors.
Shen FM; Wang J; Ni CR; Yu JG; Wang WZ; Su DF
Clin Exp Pharmacol Physiol; 2007 Aug; 34(8):702-7. PubMed ID: 17600544
[TBL] [Abstract][Full Text] [Related]
6. Ketanserin (S2-receptor blocking agents), hypertension and chronic alcoholism.
De Lorenzo A; Ceccanti M; Romeo M; Pisculli M; Di Giovanni MG; Lais A; Assogna G; Valgiusti FC
Int J Clin Pharmacol Res; 1986; 6(1):77-9. PubMed ID: 2937747
[TBL] [Abstract][Full Text] [Related]
7. Clinical aspects during therapy with the serotonin antagonist ketanserin.
Distler A
Clin Physiol Biochem; 1990; 8 Suppl 3():64-80. PubMed ID: 1983424
[TBL] [Abstract][Full Text] [Related]
8. Antihypertensive mode of action of ketanserin.
Robertson JI; Stott DJ; Ball SG
J Cardiovasc Pharmacol; 1987; 10 Suppl 3():S45-7. PubMed ID: 2446069
[TBL] [Abstract][Full Text] [Related]
9. Antihypertensive properties of ketanserin (R 41 468).
Vanhoutte PM; Van Nueten JM; Symoens J; Janssen PA
Fed Proc; 1983 Feb; 42(2):182-5. PubMed ID: 6295821
[TBL] [Abstract][Full Text] [Related]
10. Ketanserin: a new hypotensive drug?
Amery A; Fagard R; Fiocchi R; Lijnen P; Staessen J; Vanhees L
J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S176-82. PubMed ID: 2412046
[TBL] [Abstract][Full Text] [Related]
11. [Are all antihypertensive drugs renoprotective?].
Wolf S; Risler T
Herz; 2004 May; 29(3):248-54. PubMed ID: 15167950
[TBL] [Abstract][Full Text] [Related]
12. Effects of a new serotonin antagonist, ketanserin, in experimental and clinical hypertension.
Hedner T; Persson B
Am J Hypertens; 1988 Jul; 1(3 Pt 3):317S-323S. PubMed ID: 3046635
[TBL] [Abstract][Full Text] [Related]
13. Role of ketanserin in the treatment of the essential arterial hypertension associated with ischemic heart disease.
Podoleanu D; Cotoi S
Rom J Intern Med; 1996; 34(1-2):49-54. PubMed ID: 8908630
[TBL] [Abstract][Full Text] [Related]
14. [Blood pressure lowering action and tolerance of ketanserin in mono- or combination therapy].
Beretta-Piccoli C; Amstein R; Bühler FR; Bertel O; Brunner HR; Follath F; Reutter F; Vallotton MB
Schweiz Med Wochenschr; 1989 Mar; 119(12):399-406. PubMed ID: 2711155
[TBL] [Abstract][Full Text] [Related]
15. The effect of maternal ketanserin treatment on foetal 5-HT receptor function in umbilical cord artery of pre-eclamptic patients.
Hanff LM; Gupta S; MaassenVanDenBrink A; Steegers EA; Saxena PR; Vulto AG; Visser W
Neonatology; 2007; 92(4):240-7. PubMed ID: 17556842
[TBL] [Abstract][Full Text] [Related]
16. [Serotonergic antagonist].
Deguchi F; Saito T; Inagaki Y
Nihon Rinsho; 1992 Apr; 50 Suppl():770-6. PubMed ID: 1635266
[No Abstract] [Full Text] [Related]
17. [Mechanism of action and use of antagonists of serotonin receptors S2, especially ketanserin, in the treatment of various diseases of the cardiovascular system].
Wiecek A; Grzeszczak W
Pol Tyg Lek; 1987 Mar; 42(10):304-8. PubMed ID: 3299308
[No Abstract] [Full Text] [Related]
18. Differences in the acute and chronic antihypertensive mechanism of action of ketanserin in spontaneously hypertensive rats.
Balasubramaniam G; Lee HS; Mah SC
J Pharmacol Exp Ther; 1993 Jan; 264(1):129-34. PubMed ID: 8093720
[TBL] [Abstract][Full Text] [Related]
19. Ketanserin in hypertension. Early clinical evaluation and dose finding study of a new 5-HT2 receptor antagonist.
Andrén L; Svensson A; Dahlöf B; Eggertsen R; Hansson L
Acta Med Scand; 1983; 214(2):125-30. PubMed ID: 6353879
[TBL] [Abstract][Full Text] [Related]
20. Ketanserin: haemodynamic effects and mechanism of action.
Schalekamp MA; Woittiez AJ; Wenting GJ; van den Meiracker AH; Man in 't Veld AJ
J Hypertens Suppl; 1986 Apr; 4(1):S7-12. PubMed ID: 2871144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
